Abstract
Vascular-targeting antiangiogenic therapy (VTAT) of cancer can be advantageous over conventional tumor cell targeted cancer therapy if an appropriate target is found. Our hypothesis is that endoglin (ENG; CD105) is an excellent target in VTAT. ENG is selectively expressed on vascular and lymphatic endothelium in tumors. This allows us to target both tumor-associated vasculature and lymphatic vessels to suppress tumor growth and metastasis. ENG is essential for angiogenesis/vascular development and a co-receptor of TGF-β. Our studies of selected anti-ENG monoclonal antibodies (mAbs) in several animal models and in vitro studies support our hypothesis. These mAbs and/or their immunoconjugates (immunotoxins and radioimmunoconjugates) induced regression of preformed tumors as well as inhibited formation of new tumors. In addition, they suppressed metastasis. Several mechanisms were involved in the suppressive activity of the naked (unconjugated) anti-ENG mAbs. These include direct growth suppression of proliferating endothelial cells, induction of apoptosis, ADCC (antibody-dependent cell-mediated cytotoxicity) and induction of T cell immunity. To facilitate clinical application, we generated a human/mouse chimeric anti-ENG mAb termed c-SN6j and performed studies of pharmacokinetics, toxicology and immunogenicity of c-SN6j in nonhuman primates. No significant toxicity was detected by several criteria and minimal immune response to the murine part of c-SN6j was detected after multiple i.v. injections. The results support our hypothesis that c-SN6j can be safely administered in cancer patients. This hypothesis is supported by the ongoing phase 1 clinical trial of c-SN6j (also known as TRC105) in patients with advanced or metastatic solid cancer in collaboration with Tracon Pharma and several oncologists (NCT00582985).
Keywords: Endoglin, CD105, Anti-endoglin antibody, vascular-targeting therapy, antiangiogenic therapy, chimeric antibody, Vascular-targeting antiangiogenic therapy, VTAT, tumor heterogeneity, Immunohistochemical (IHC), immunoliposomes, MCF-7 tumors, cyclophosphamide, oligodeoxynucleotides, c-SN6j, doxorubicin
Current Drug Delivery
Title: Endoglin-Targeted Cancer Therapy
Volume: 8 Issue: 1
Author(s): Ben K. Seon, Akinao Haba, Fumihiko Matsuno, Norihiko Takahashi, Masanori Tsujie, Xinwei She, Naoko Harada, Shima Uneda, Tomoko Tsujie, Hirofumi Toi, Hilda Tsai and Yuro Haruta
Affiliation:
Keywords: Endoglin, CD105, Anti-endoglin antibody, vascular-targeting therapy, antiangiogenic therapy, chimeric antibody, Vascular-targeting antiangiogenic therapy, VTAT, tumor heterogeneity, Immunohistochemical (IHC), immunoliposomes, MCF-7 tumors, cyclophosphamide, oligodeoxynucleotides, c-SN6j, doxorubicin
Abstract: Vascular-targeting antiangiogenic therapy (VTAT) of cancer can be advantageous over conventional tumor cell targeted cancer therapy if an appropriate target is found. Our hypothesis is that endoglin (ENG; CD105) is an excellent target in VTAT. ENG is selectively expressed on vascular and lymphatic endothelium in tumors. This allows us to target both tumor-associated vasculature and lymphatic vessels to suppress tumor growth and metastasis. ENG is essential for angiogenesis/vascular development and a co-receptor of TGF-β. Our studies of selected anti-ENG monoclonal antibodies (mAbs) in several animal models and in vitro studies support our hypothesis. These mAbs and/or their immunoconjugates (immunotoxins and radioimmunoconjugates) induced regression of preformed tumors as well as inhibited formation of new tumors. In addition, they suppressed metastasis. Several mechanisms were involved in the suppressive activity of the naked (unconjugated) anti-ENG mAbs. These include direct growth suppression of proliferating endothelial cells, induction of apoptosis, ADCC (antibody-dependent cell-mediated cytotoxicity) and induction of T cell immunity. To facilitate clinical application, we generated a human/mouse chimeric anti-ENG mAb termed c-SN6j and performed studies of pharmacokinetics, toxicology and immunogenicity of c-SN6j in nonhuman primates. No significant toxicity was detected by several criteria and minimal immune response to the murine part of c-SN6j was detected after multiple i.v. injections. The results support our hypothesis that c-SN6j can be safely administered in cancer patients. This hypothesis is supported by the ongoing phase 1 clinical trial of c-SN6j (also known as TRC105) in patients with advanced or metastatic solid cancer in collaboration with Tracon Pharma and several oncologists (NCT00582985).
Export Options
About this article
Cite this article as:
K. Seon Ben, Haba Akinao, Matsuno Fumihiko, Takahashi Norihiko, Tsujie Masanori, She Xinwei, Harada Naoko, Uneda Shima, Tsujie Tomoko, Toi Hirofumi, Tsai Hilda and Haruta Yuro, Endoglin-Targeted Cancer Therapy, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663570
DOI https://dx.doi.org/10.2174/156720111793663570 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Obesity and Pregnancy
Current Women`s Health Reviews New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Zeolitic Imidazolate Frameworks (ZIF-8) for Biomedical Applications: A Review
Current Medicinal Chemistry Cytotoxicity and Toxicological Studies of <i>Artocarpus altilis</i> Extracts, Inducing Apoptosis and Cell Cycle Arrest via <i>CASPASE-3</i> and <i>CASPASE-8</i> Pathways against Human Breast MCF-7 Cells
Combinatorial Chemistry & High Throughput Screening Diagnostic Devices for Circulating Biomarkers Detection and Quantification
Current Medicinal Chemistry Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2
Current Vascular Pharmacology Advances in Research on the Preparation and Biological Activity of Maslinic Acid
Mini-Reviews in Medicinal Chemistry Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism <I>In-silico</I> Molecular Interaction of Short Synthetic Lipopeptide/Importin-alpha and <I>In-vitro</I> Evaluation of Transgene Expression Mediated by Liposome- Based Gene Carrier
Current Gene Therapy Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Application of a Deep Matrix Factorization Model on Integrated Gene Expression Data
Current Bioinformatics New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Editorial [Hot Topic: Diagnostic and Therapeutic Optical Imaging Techniques]
Current Medical Imaging Design, Synthesis and In Vitro Anticancer Activity of a New Class of Bifunctional DNA Intercalators
Letters in Drug Design & Discovery